Chronic Obstructive Pulmonary Disease (COPD): A High-Yield USMLE Review
COPD is a largely irreversible obstructive lung disease combining emphysema (parenchymal destruction) and chronic bronchitis (airway disease), usually caused by smoking and occasionally by alpha-1 antitrypsin deficiency. It is a leading cause of chronic dyspnea and is tested through its spirometric definition, GOLD staging, exacerbation management, and its distinction from asthma and other causes of dyspnea.
Pathophysiology
Chronic airway injury (usually from cigarette smoke) drives emphysematous destruction of lung parenchyma and inflammatory airway disease, producing airflow limitation that is only minimally reversible. During expiration the loss of elastic recoil and positive pleural pressure cause dynamic collapse of floppy airways, while mucus plugging and airway wall thickening further narrow the lumen—this is why obstruction affects expiration more than inspiration. The emphysematous destruction creates V/Q mismatch and impaired ventilation, yielding hypoxemia with a widened A-a gradient and CO2 retention. In alpha-1 antitrypsin deficiency, absent inhibition of neutrophil elastase allows unopposed proteolysis of lung tissue, producing early panacinar, lower-lobe emphysema.
Presentation
- Chronic, progressive dyspnea developing over months to years, typically in a long-term smoker (e.g., high pack-year history)
- Prolonged expiratory phase and pursed-lip breathing, which creates back-pressure to keep floppy airways splinted open longer
- Tripod positioning (leaning forward, hands on knees) and accessory muscle use during exacerbation
- Exacerbations with worsening dyspnea and increased purulent sputum, often driven by respiratory infection
- ABG pattern of chronic CO2 retention (elevated PaCO2) with compensatory elevated bicarbonate, plus a mildly elevated A-a gradient from V/Q mismatch in emphysematous lungs
Diagnosis
- Spirometry confirms the diagnosis: FEV1/FVC < 0.70 (or below the lower limit of normal) with limited bronchodilator response, though some response does not exclude COPD
- GOLD spirometric severity graded by FEV1 % predicted: GOLD 1 (≥80%), GOLD 2 (50–79%), GOLD 3 (30–49%), GOLD 4 (<30%)
- ABG in exacerbation may show acute-on-chronic respiratory acidosis (low pH, elevated PaCO2) with hypoxemia, guiding the need for ventilatory support
- Alpha-1 antitrypsin testing in patients with early-onset emphysema (young age, minimal/no smoking, lower-lobe panacinar disease)
Management
- Bronchodilators are first-line: SABA (albuterol) for rescue, with LAMA (tiotropium) and/or LABA for maintenance; LAMA may be more effective than LABA for COPD. Escalate per ABCD groups (Group A: LAMA or LABA; Group B: LAMA+LABA; Group E: LAMA+LABA)
- Inhaled corticosteroids are added to long-acting bronchodilators in patients with frequent exacerbations, blood eosinophils ≥300 cells/µL, or asthma-COPD overlap—used judiciously because ICS increases pneumonia risk
- Smoking cessation is the only intervention proven to slow disease progression; offer pharmacotherapy (varenicline, bupropion, nicotine replacement) and counseling
- Pulmonary rehabilitation, vaccinations (influenza, pneumococcal, COVID-19, Tdap, zoster), and supplemental oxygen for resting PaO2 ≤55 mmHg or SpO2 ≤88% (or PaO2 56–59 with cor pulmonale)
- Acute exacerbation with hypercapnic respiratory acidosis: initiate BiPAP (reduces work of breathing, intubation rates, and mortality), plus controlled oxygen targeting SpO2 88–92%, nebulized SABA/SAMA, systemic corticosteroids, and antibiotics when sputum is purulent
High-yield
- FEV1/FVC < 0.70 defines obstruction; GOLD stages severity by FEV1 % predicted, but the ABCD tool also incorporates symptom burden and exacerbation history
- Alpha-1 antitrypsin deficiency: young non-smoker with lower-lobe panacinar emphysema; the Z mutation misfolds in hepatocytes causing neonatal hepatitis, cirrhosis, and hepatocellular carcinoma risk
- Smoking cessation is the ONLY intervention that slows COPD progression
- BiPAP is the key intervention for COPD exacerbation with hypercapnic respiratory acidosis—reduces intubation and mortality
- H. influenzae and Moraxella catarrhalis are common causes of COPD infections/exacerbations; give oxygen targeting 88–92% to avoid worsening CO2 retention
- PAH-specific therapies (e.g., sildenafil) are NOT recommended in Group 3 pulmonary hypertension due to COPD—vasodilators can worsen V/Q matching
Pitfalls
- Do not assume 'wheezing = asthma'—COPD is largely irreversible, whereas asthma features reversible obstruction and Th2-mediated inflammation; always confirm with objective spirometry
- In exacerbation, do not withhold BiPAP in favor of proceeding directly to intubation when the patient has hypercapnic respiratory acidosis—BiPAP is first-line and lowers intubation and mortality
- Overusing inhaled corticosteroids in COPD is a trap: reserve for exacerbators with eosinophilia or asthma-COPD overlap, since ICS increases pneumonia risk
- Do not attribute acute-onset dyspnea (seconds to hours) in a COPD patient purely to the COPD—worsening COPD is a classic atypical presentation of pulmonary embolism
- Missing alpha-1 antitrypsin deficiency in a young non-smoker with lower-lobe emphysema by assuming all emphysema is smoking-related (which is typically upper-lobe)
Don't just memorize Chronic Obstructive Pulmonary Disease (COPD) — practice reasoning through it on branching cases where your decisions shape the patient.